PANK1 and Alzheimer disease: PZ-2891 was initially designed as a nonselective modulator of PANK, the rate-limiting enzyme for CoA biosynthesis, while the RT–qPCR and WB results revealed that it more strongly modulated PANK2 than other subtypes in AD pathology.